BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:


  • Essential mineral extraction: The Company’s extraction of individual macro minerals and micro minerals from seaweed and sea plant biomass, to enable the sale of those macro and micro minerals to the commodities markets, and to industry specific markets such as the battery industry, and thereby create an additional revenue stream for the Company; and
  • Seaweed and Blue Carbon Credits: The Company’s sale of seaweed cellulose fibre as a filler in biopolymer, bioplastic and battery electrolyte solution separator materials as revenue streams for the Company and to serve as a means of evidencing carbon sequestration and storage for the purposes of qualifying for blue carbon credits. On receipt of the blue carbon credits, the Company would seek to sell those blue carbon credits as an additional revenue stream. (Together, the New Projects)
Highlights
  • R&D program now includes:
    • Essential Mineral Extraction: extraction of seaweed-based individual macro & micro minerals for sale into the commodities markets and industry specific markets like the battery and energy industries;
    • Artificial Intelligence technology (AI): AI to be developed and deployed to enhance nutraceutical and essential mineral identification and extraction; and
    • Carbon Credits: sale of seaweed cellulose fibre to the building materials and battery industries to attract Carbon Credits.
  • R&D program focussed on potential commercialisation opportunities.
The research and development (R&D) that the Company intends to undertake on the New Projects is in addition to the Company’s existing R&D activity which is focusses on:
  • Edible bird’s nest product enhancement by the infusion of seaweed-derived nutrients; and
  • Creation of a range of prototypes for food products, dietary supplements, healthcare products, and cosmetic applications that incorporate seaweed-sourced and/or bird’s nest-sourced nutraceuticals.

ASX Listing Rule 11.1.2 doesn’t apply to the expanded “nature” of the Company’s business

Following its review of the Company’s submission letter, the Company has received notice from ASX that the expenditure of $250,000 to investigate the possibilities of the New Projects will not attract the application of Listing Rules 11.1.2. The Company will notify ASX once anything eventuates from the R&D on the New Projects, and if the Company decides to pursue further opportunities, to report to ASX on the size and scope of the further developments.

Essential Mineral Extraction

Seaweed in general has a chemical composition significant in polysaccharides (agar), essential minerals and trace elements, although the composition varies from species to species. The target compounds of interest to the Company will affect the choice of species selection for the sake of commercial production and will also affect the method of post-harvest treatment and extraction for specific compounds.

For essential mineral extraction for sale into the commodities markets and for use in the battery technology and energy production industries, the initial specific focus is on nickel and cobalt. The Company is also monitoring the results of published research regarding the use of seaweed-derived chemicals and cellulose micromaterials in enhancing battery performance. Examples of recently published studies include the improvement made by added cellulose micromaterials to battery separators in sodium-metal batteries and to a prototype battery electrode made from a combination of silicon and a seaweed-derived alginate which improved the electrode’s elasticity and ability to store energy. The Company regards itself as a potential supplier of essential minerals, including these seaweed-derived cellulose micromaterials and alginates, to the current and emerging battery technology and battery manufacturing industries.

Regarding essential mineral extraction for use in vitamin supplement manufacture, the Company’s specific focus is on trace metals that are established by science to occur in rich concentrations in seaweed: nickel, cobalt and manganese. These minerals are common trace elements in vitamin supplements.


Click here for the full ASX Release

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BP8:AU
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BPH Global

BPH Global

Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment being sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product includes Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.
Radiopharm Theranostics

Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024.

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
BPH Global

BPH Global Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×